The Ethical Hazards and Programmatic Challenges of Genomic Newborn Screening

Aaron J. Goldenberg, PhD, MPH
Richard R. Sharp, PhD

Advances in next-generation sequencing technologies have the potential to spur better integration of genetic testing into patient care. Appropriate utilization of these technologies will require the capacity to manage, interpret, and communicate large amounts of personal genetic information. Because the clinical infrastructure necessary to support these activities is currently limited, it is likely that the earliest applications of whole-genome sequencing will be restricted to settings in which genetic testing is already a routine part of clinical or public health practice, such as state newborn screening (NBS) programs.

The use of next-generation sequencing will enable the detection of a larger number of deleterious genetic variants, thereby expanding the number of pediatric disorders evaluated without substantially increasing the costs of NBS. These important public health goals may encourage early adoption of whole-exome and whole-genome sequencing by state NBS programs. However, if implemented by state programs, new sequencing technologies may have a number of undesirable effects that threaten the moral foundation and core mission of one the nation’s most successful public health initiatives.

For nearly half a century, state NBS programs have tested millions of children annually to identify medical conditions that, if untreated, result in severe physical, mental, or developmental harms. The child welfare considerations that support these public health initiatives are compelling and have prompted most states to require NBS for all children, often with significant limitations on parents’ ability to request an exemption. The moral justification for compulsory NBS screening derives from the state’s interest in protecting its most vulnerable citizens from preventable harm. Although the diseases evaluated by these programs are exceptionally rare, the opportunity to intervene and dramatically alter a child’s life course and expectancy has been regarded as sufficient to preempt any claims of parental autonomy.

As programs have evolved over the last 40 years, there have been a number of challenges to the moral justification on which mandatory NBS was founded. With the introduction of tandem-mass spectrometry in the mid-1990s, state screening programs began evaluating greater numbers of metabolic and genetic conditions. Whereas it was typical for states to test for an average of 5 conditions in 1995, by 2005 states were testing for an average of 24 genetic diseases, an increase of more than 350%. Some states evaluate dozens of additional conditions, including diseases that affect children at a later stage in development and others for which the benefits of early intervention are limited.

Critics have questioned whether in adding testing for these new conditions, state NBS programs have strayed too far from their core aims as public health programs. For these critics, NBS is justifiable as a compulsory, state-supported activity to the extent that these programs protect the welfare of newborn children by identifying diseases that require immediate medical action in order to avert a catastrophic outcome. Others have voiced concerns about the lack of clinical data establishing the utility of expanded screening. These objections signal a basic concern about expanded NBS—that more expansive screening may fail to meet the medical requirements necessary to justify compulsory testing.

These debates may be amplified as states consider using next-generation sequencing within NBS programs. Several national discussions have begun to consider use of genome sequencing technologies in NBS, including a recent meeting convened by the National Institutes of Health. If these technologies are used by state NBS programs, several ethical hazards will need to be navigated. First, multiplexed forms of genetic testing have already raised questions about the ability of clinicians to interpret and effectively communicate the deluge of genetic data generated by these genotyping methods. Use of genomic methods in NBS would amplify these concerns, as program directors struggle to decide what information should be disclosed to parents. Returning genetic results that do not require immediate medical action or results for which clinical implications are unclear may create unwanted psychosocial burdens on parents. These and other information-management challenges will be far...
more common and difficult to manage if genomic sequencing methods are adopted by state health departments, with potential to overwhelm the capacity of state NBS programs.\textsuperscript{3} While requirements to seek parental consent for NBS may help to address some of these concerns,\textsuperscript{8} implementation of any type of consent process would require programs to make difficult decisions about what types of information to offer to parents, including, for example, whether to provide parents with results regarding conditions for which medical intervention is of uncertain benefit. Before implementing genomic screening, state health departments would also need to consider available clinical resources for ensuring adequate pretest and posttest counseling about genetic test results.

A second area of concern centers on how states would utilize the vast amounts of information generated by use of genomic technologies in NBS. State storage of these data may lead some parents to view genomic evaluation of newborns as a form of research. As a result, if NBS continues to be a mandatory test—required of all children with limited options available to parents who wish to avoid participation—members of the public who feel their privacy is being violated may mobilize politically in opposition to mandatory NBS programs. These concerns are already evident in current debates about the storage and use of residual NBS bloodspots for research, which has resulted in fears of higher numbers of parents opting out of testing and lawsuits challenging NBS by parents in Texas and Minnesota.\textsuperscript{9}

Third, genomic screening would represent an even greater departure from the core public health aims served by NBS than other recent extensions of these programs. Since its inception, NBS has saved thousands of children from the effects of devastating genetic diseases. While program improvement should always be a goal, the use of genomic sequencing methods has potential to erode the foundation of NBS, possibly resulting in greater numbers of children with genetic disease going undetected. Many parents may voice objections to the government sequencing their child’s genome, especially if this is done in the context of a compulsory public health program, undermining public confidence in state NBS programs and potentially threatening their political tenability. Some have suggested that a tiered consent process in which some tests are mandatory and others are elective may help to address these concerns.\textsuperscript{10} Implementing this approach in state NBS programs would represent a major shift from the core public health principles that have anchored public support for these programs, potentially resulting in larger numbers of parents choosing to forgo screening altogether.

These ethical and practical concerns highlight how the use of genomic technologies poses a significant threat to state NBS programs, as these programs move ever further from their core protectionist mission. In this regard, the use of genome sequencing methods in state NBS programs may undermine the child welfare goals on which mandatory NBS programs are founded. As the ability to interpret data generated by next-generation sequencing increases, ongoing dialogue among screening programs, genome scientists, primary care physicians, and parents will be essential for assessing where, and how, these technologies should be used. Even though the implementation of genomic technology may improve the quality of NBS, premature adoption of these tools could ultimately place children at risk.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Funding/Support: This work was funded by grant R01HG004500 and P50HG003390 from the National Human Genome Research Institute.

Role of the Sponsor: The National Human Genome Research Institute had no role in the preparation, review, or approval of the manuscript.

Disclaimer: The content is solely the responsibility of the authors and does not represent the official views of the National Human Genome Research Institute or National Institutes of Health.

Additional Contributions: We thank Wylie Burke, MD, PhD (University of Washington), Beth Tarini, MD, MS (University of Michigan), Shawn McCandless, MD (Case Western Reserve University), and Benjamin Wilfond, MD (University of Washington), for their useful comments on this article.

REFERENCES